Oral Progesterone Regimen for Dysfunctional Uterine Bleeding
For adult women with dysfunctional uterine bleeding (DUB), prescribe medroxyprogesterone acetate (MPA) 10 mg orally daily for 10-14 days per month (typically days 16-25 of the cycle), repeated for at least 3-6 months. This regimen effectively controls bleeding in most women with anovulatory DUB while minimizing side effects 1, 2.
Treatment Algorithm Based on Clinical Context
For Anovulatory DUB (Most Common)
First-line approach:
- Medroxyprogesterone acetate (MPA) 10 mg daily for 10 days each month (days 16-25 of cycle)
- Continue for minimum 3 months, monitor closely thereafter 2
- Recent evidence shows the 10-day protocol (days 16-25) is superior to 15-day protocols for achieving regular cycles and stopping bleeding 1
Alternative regimens if MPA unavailable:
- Norethisterone 5-10 mg three times daily, days 5-25 of cycle 3
- Micronized progesterone 200 mg daily for 12-14 days per month 4
For Acute Heavy Bleeding Episodes
Immediate control regimen:
- Depo-medroxyprogesterone acetate 150 mg IM injection PLUS
- Oral MPA 20 mg every 8 hours for 3 days (9 doses total)
- This combination stops bleeding in nearly all women within 2-3 days 5
Special Populations
Adolescents:
- MPA 10 mg daily for 10 days monthly, minimum 3 months
- Monitor closely after initial treatment course 2
Perimenopausal women:
- Cyclic MPA 10 mg for days 18-25 of a 25-day cycle
- May combine with conjugated estrogens if needed 2
Women requiring contraception:
- Consider combined oral contraceptives instead of progestin-only therapy 6
Key Evidence Supporting This Approach
The 10-day luteal phase protocol (days 16-25) demonstrates superior outcomes compared to longer 15-day regimens, with better cycle regulation and more frequent bleeding cessation after just 3 treatment cycles 1. This challenges older protocols that recommended longer treatment durations.
Micronized progesterone (MP) is theoretically preferred over synthetic progestins due to lower cardiovascular and thrombotic risk 4, though this evidence comes primarily from hormone replacement therapy literature rather than DUB-specific studies. In practical terms, MPA remains the most studied and accessible option for DUB management.
Important Caveats
Luteal phase progestin therapy is significantly less effective than:
- Tranexamic acid for reducing menstrual blood loss 7
- Levonorgestrel IUD for long-term management 7
- NSAIDs show a strong trend toward superiority 7
Before initiating treatment, exclude:
- Pregnancy (always rule out first)
- Structural pathology (polyps, fibroids, malignancy)
- Coagulopathy (especially von Willebrand disease, present in ~1% of women with heavy bleeding) 2
- Thyroid disease, hyperprolactinemia 6
Treatment failure indicators:
- If bleeding persists after 3-6 months of cyclic progestin therapy
- Consider alternative diagnoses or structural causes
- May need endometrial biopsy if risk factors present (age >45, obesity, PCOS, prolonged anovulation) 6
Why This Regimen Works
Progestins stabilize the endometrium by opposing unopposed estrogen stimulation that occurs in anovulatory cycles. The luteal phase timing (days 16-25) mimics natural progesterone secretion, providing endometrial support and organized withdrawal bleeding 1. The 10-day duration appears optimal for balancing efficacy with minimal side effects and better compliance.
For women with ovulatory DUB (less common, characterized by regular cycles with heavy flow), this regimen is less effective 3, 7. These patients may require longer treatment courses (days 5-25) or alternative therapies like NSAIDs or tranexamic acid.
Practical Implementation
- Start treatment regardless of cycle day if bleeding is ongoing
- Expect withdrawal bleeding 2-7 days after completing each progestin course
- Side effects are generally mild (bloating, mood changes, breast tenderness)
- Patient satisfaction is typically high with this outpatient approach 5
- If acute bleeding requires immediate control, use the combination IM/oral protocol described above